- Datum11.09.2024
- Uhrzeit15:00 - 15:30 Uhr
- Veranstalter
stock3
Du willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnen![stock3 Terminal Chart](/img/banner/chart-light.png)
Ionis Pharmaceuticals Inc. Kurse
Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
---|---|---|---|---|---|---|
L&S | VK | |||||
Tradegate | VK | |||||
Stuttgart | VK |
Passende Produkte
WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
---|
Wertentwicklung (Nasdaq)
Wikifolio
Passender Service zu Ionis Pharmaceuticals Inc.
Webinar zu Ionis Pharmaceuticals Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)35,950-54,445
- Jahrestief / Hoch ($)35,950-54,445
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Ionis Pharmaceuticals Inc.
Termine von Ionis Pharmaceuticals Inc.
- Okt31Ionis Pharmaceuticals Inc.Q3 2024 Earnings Release
- Feb19Ionis Pharmaceuticals Inc.Q4 2024 Earnings Release
- Apr30Ionis Pharmaceuticals Inc.Q1 2025 Earnings Release
Beschreibung
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.